Physician profile
Samir Patel
NPI 1588659296
$2,993.35
in general payments reported to CMS, 2019-2025
26 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $171 · 2021: $429 · 2022: $419 · 2023: $351 · 2024: $267 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.47 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $829.48 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Cook Incorporated | $474.22 | 2019 | |
| Novo Nordisk INC | $300.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $150.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $138.89 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $133.30 | 2019-2025 | |
| Astellas Pharma US INC | $97.10 | 2020-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.38 | 2019-2022 | |
| Pfizer INC. | $88.10 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.38 | 2022-2025 | |
| Abbvie INC. | $87.33 | 2021-2024 | |
| Lilly USA, LLC | $65.57 | 2019 | |
| Abbott Laboratories | $59.77 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $59.10 | 2022-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $58.34 | 2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $44.43 | 2022 | |
| Amarin Pharma, INC. | $42.42 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.60 | 2021 | |
| Merck Sharp & Dohme LLC | $26.23 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $25.70 | 2021-2024 | Rexulti |
| Allergan, INC. | $25.38 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.67 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.50 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $14.32 | 2024 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $14.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.